Skip to Content
Merck
CN
  • P38 initiates degeneration of midbrain GABAergic and glutamatergic neurons in diabetes models.

P38 initiates degeneration of midbrain GABAergic and glutamatergic neurons in diabetes models.

The European journal of neuroscience (2022-05-06)
Aisan Farhadi, Mehdi Totonchi, Seyed Masood Nabavi, Hossein Baharvand, Hossein Pakdaman, Ensiyeh Hajizadeh-Saffar, Seyed Ahmad Mousavi, Fatemeh Hadi, Hamed Al-Sinawi, Quan Li, Jin-San Zhang, Yaser Tahamtani, Koorosh Shahpasand
ABSTRACT

Diabetes mellitus may cause tau protein hyperphosphorylation and neurodegeneration, but the exact mechanism by which diabetic conditions induce tau pathology remains unclear. Tau protein hyperphosphorylation is considered a major pathological hallmark of neurodegeneration and can be triggered by diabetes. Various tau-directed kinases, including P38, can be activated upon diabetic stress and induce tau hyperphosphorylation. Despite extensive research efforts, the exact tau specie(s) and kinases driving neurodegeneration in diabetes mellitus have not been clearly elucidated. We herein employed different techniques to determine the exact molecular mechanism of tau pathology triggered by diabetes in in vivo and in vitro models. We showed that diabetes-related stresses and glucose metabolism deficiency could induce cis P-tau (an early driver of the tau pathology) accumulation in the midbrain and corpus callosum of the diabetic mice models and cells treated with 2-deoxy-D-glucose, respectively. We found that the active phosphorylated level of P38 was increased in the treated cells and diabetic mice models. We observed that oxidative stress activated P38, which directly and indirectly drove tau pathology in the GABAergic and glutamatergic neurons of the midbrain of the diabetic mice after 96 h, which accumulated in the other neighboring brain areas after 2 months. Notably, P38 inhibition suppressed tau pathogenicity and risk-taking behaviors in the animal models after 96 h. The data establish P38 as a central mediator of diabetes mellitus-induced tau pathology. Our findings provide mechanistic insight into the consequences of this metabolic disorder on the nervous system.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Anti-MAP2 (2a+2b) antibody, Mouse monoclonal, clone AP-20, ascites fluid
Sigma-Aldrich
2-Deoxy-D-glucose, ≥98% (GC), crystalline
Sigma-Aldrich
Phosphatase Inhibitor Cocktail 1, DMSO solution
Sigma-Aldrich
Protease Inhibitor Cocktail powder, for general use, lyophilized powder
Sigma-Aldrich
Anti-Glutamic Acid Decarboxylase 65/67 antibody produced in rabbit, IgG fraction of antiserum, buffered aqueous solution
Sigma-Aldrich
SB 203580, solid, ≥98% (HPLC)
Sigma-Aldrich
Laminin from Engelbreth-Holm-Swarm murine sarcoma basement membrane, 1-2 mg/mL in Tris-buffered saline, 0.2 μm filtered, BioReagent, suitable for cell culture
Sigma-Aldrich
HEPES solution, 1 M, pH 7.0-7.6, sterile-filtered, BioReagent, suitable for cell culture
Roche
DNase I, from bovine pancreas
Millipore
IHC Select Proteinase K
Sigma-Aldrich
Anti-Tau Antibody, a.a. 210-241, clone Tau-5, ascites fluid, clone Tau-5, Chemicon®